Masitinib in combination with Rilutek reduced ALS progression by 27%
Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with amyotrophic lateral sclerosis (ALS) who have a typical disease progression, according to the final report of AB Science‘s Phase 2/3 clinical trial.
At 11 months of treatment with the combo, the rate of disability progression was reduced by 27%, as compared to a placebo plus Rilutek. In contrast, patients who have a faster disease worsening do not benefit as much from adding masitinib to their treatment.AB Science is now setting up a Phase 3 trial to confirm the latest results and gather more data in support of a new marketing application to the European Medicine Agency (EMA). Here is a link to their clinical trial planned to begin in November, 2019.Would you consider participating? What are your thoughts about Masitinib?
Sorry, there were no replies found.
Log in to reply.